Company Filing History:
Years Active: 2024
Title: Hanno SJUTS - Innovator in Antibody Therapeutics
Introduction
Hanno SJUTS is a notable inventor based in Frankfurt-am-Main, Germany, recognized for his exceptional contributions to the field of biotechnology. His innovative work focuses on the development of therapeutic antibodies, exemplified by his patented invention aimed at treating autoimmune and autoinflammatory diseases.
Latest Patents
Hanno SJUTS holds a patent for a "Humanized anti-IL-1R3 antibody and methods of use." This patent describes an antibody specifically designed to bind to IL-1R3, featuring a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2. The patent further details a pharmaceutical composition that includes this antibody along with a pharmaceutically acceptable diluent, carrier, or excipient. This antibody is intended for use in treating various diseases or disorders in individuals who are in need, particularly targeting autoimmune or autoinflammatory conditions.
Career Highlights
Hanno currently works at Sanofi Biotechnology, a leading company in the field of biopharmaceuticals. Throughout his career, he has demonstrated a strong commitment to advancing medical treatments through innovative research. His work has significant implications for patients suffering from conditions that currently lack effective therapies.
Collaborations
In his professional journey, Hanno has collaborated with talented individuals such as Christian Lange and Ziyu Li. These partnerships have fostered a dynamic research environment, contributing to groundbreaking solutions in biotechnology.
Conclusion
Hanno SJUTS continues to be a driving force in antibody research and development. His patented invention not only reflects his dedication to innovation but also holds promise for improved treatments for patients facing challenging autoimmune disorders. As he further explores the potential of antibody therapeutics within the biotechnology landscape, the impact of his work is expected to expand significantly.